期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 78, 期 3, 页码 252-259出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2010.05.007
关键词
Age; Comorbidity; Chemotherapy; Pancreatic cancer; Gemcitabine
Objective: To evaluate the impact of age and comorbidity on clinical outcomes in advanced pancreatic cancer. Methods: Consecutive 237 patients with advanced pancreatic cancer were studied. Comorbidity was scored by Charlson comorbidity index (CCI). We compared the clinical outcomes by age or comorbidity. Results: Sixty-nine patients were elderly (>= 75 years), and CCI was 0 in 69 patients, 1 in 98, and >= 2 in 70. Gemcitabine-based chemotherapy was administered in 183 patients and was well tolerated in both elderly group and in those with comorbidities. In a multivariate analysis, CCI, not age, was prognostic in addition to PS, distant metastasis, chemotherapy and CA 19-9: the hazard ratios of CCI 1 and >= 2 were 1.25 and 1.55, compared with CCI 0 (p=0.027). Conclusions: Gemcitabine-based chemotherapy can be an effective treatment, without significant toxicity, in elderly patients. Comorbidity, not age, was prognostic in patients with advanced pancreatic cancer. (C) 2010 Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据